“Tacrine, also known as its brand name Cognex, was the first drug approved by the FDA for the treatment of Alzheimer’s disease.

At the time of its approval in 1993, tacrine was considered an effective therapy for mild-to-moderate Alzheimer’s. The drug was able to pass through the blood-brain barrier quickly, a significant feat when it comes to treating brain disorders, and research showed that it was actually able to boost cognitive function in people with Alzheimer’s.

Tacrine fell out of use by 2013, when it was withdrawn from the market due to concerns over its link to liver toxicity. But its legacy led to improved drugs that are now beneficial to Alzheimer’s patients, and it paved the way for research into future therapies that aim to slow the progression of the disease.”


Read more here.